title: Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis.
abstract: Prognostic value of FGF23 in end-stage renal disease (ESRD) patients is controversial. A systematic review was conducted to quantify the association between elevated FGF23 and overall mortality among ESRD patients.
  
  
  
  MEDLINE, EMBASE, PubMed and reference lists were searched. Quality of the included studies was evaluated using Newcastle-Ottawa Scale checklist. Pooled effects were calculated as hazard ratio using fixed-effect models, and chi-square test was used for heterogeneity testing.
  
  
  
  Seven studies (1406 patients) were included. Patients were at mean age of 62.3. Mean follow-up was 29.4 months. From the pooled analysis, elevated FGF23 was significantly associated with increased all-cause mortality (hazard ratio: 1.53; 95% CI: 1.05-2.25). p-value for heterogeneity was 0.10, I(2) = 48%.
  
  
  
  ESRD patients with elevated FGF23 concentration have higher risk of death.
authors.affiliation: Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Hongliu
authors.initials: H
authors.lastname: Yang
authors.affiliation: Division of Thyroid surgery, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Han
authors.initials: H
authors.lastname: Luo
authors.affiliation: Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Tang
authors.affiliation: Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Xiaoxi
authors.initials: X
authors.lastname: Zeng
authors.affiliation: Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Ma
authors.affiliation: Division of Nephrology, Kidney Research Institute, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Fu
mesh_terms: D015415:Biomarkers / Q000097:blood; D016208:Databases, Factual; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007676:Kidney Failure, Chronic / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D016017:Odds Ratio; D016016:Proportional Hazards Models
chemical_list: D015415:Biomarkers; C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23
keywords: FGF23; dialysis; end-stage renal disease; mortality